Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
Add to list
  1. Search results
  2. Nitinol stent implantation in long su...

Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study

Marc Bosiers, Giovanni Torsello, Hans-Martin Gissler, Johannes Ruef, Stefan Muller-Hulsbeck, Thomas Jahnke, Patrick Peeters (UGent) , Kim Daenens, Johannes Lammer, Herman Schroe, et al.
(2009) JOURNAL OF ENDOVASCULAR THERAPY. 16(3). p.261-269
Author
Organization
Abstract
Purpose:To evaluate the long-term efficacy and integrity of the PROTEGE EverFlex stent in superficial femoral artery (SFA) lesions in symptomatic patients with peripheral artery disease (PAD). Methods: A prospective, multicenter, nonrandomized study enrolled 151 subjects (111 men; mean age 67.8 years, range 42-93) undergoing percutaneous treatment of de novo, restenotic, or reoccluded SFA lesions between August 11, 2006, and June 26, 2007. Subjects were scheduled to receive a single stent and be evaluated through 12 months following the implant procedure. Occlusions were present in 40% of the patients. Mean lesion length was 96.4 mm (range 10-150). Results: A total of 161 stents (158 EverFlex) were implanted in the 151 patients: single stents in 93.4% (141/151) and a second stent in 6.6% (10/151). One-year follow-up information was available for 88.7% (134/151) of the study participants; of the remaining 17 subjects, 6 subjects withdrew from the study, 2 were lost to follow-up, and 9 died. Freedom from restenosis data were available for 99.3% (133/134) of the subjects who completed a 12-month follow-up visit. The mean Rutherford classification fell from 2.8 +/- 0.8 (range 1-5) at baseline to 0.6 +/- 1.1 (range 0-5) at 12 months. The mean ankle-brachial index rose from 0.6 +/- 0.2 (range 0-1.4) at baseline to 0.9 +/- 0.2 (range 0-1.2) at 12 months. The rates for freedom from >50% restenosis at 6 and 12 months were 91.3% (95% Cl 84.9% to 95.2%) and 72.2% (95% Cl 63.8% to 79.6%), respectively. The freedom from target lesion revascularization rate at 12 months was 79.1% (95% Cl 71.2% to 85.6%). The 1-year stent fracture rate was 8.1% (95% Cl 4.0% to 14.4%). Conclusion: The high freedom from >50% restenosis and low fracture rate at 12 months suggests that the PROTEGE EverFlex stent offers a safe and acceptably efficacious means of treating SFA lesions in symptomatic subjects with PAD. J Endovasc Ther. 2009;16:261-269
Keywords
occlusions, stenosis, restenosis, TRIAL, stent fracture, outcome analysis, ANGIOPLASTY, peripheral artery disease, superficial femoral artery

Citation

Please use this url to cite or link to this publication:

MLA
Bosiers, Marc, et al. “Nitinol Stent Implantation in Long Superficial Femoral Artery Lesions: 12-Month Results of the DURABILITY I Study.” JOURNAL OF ENDOVASCULAR THERAPY, vol. 16, no. 3, 2009, pp. 261–69, doi:10.1583/08-2676.1.
APA
Bosiers, M., Torsello, G., Gissler, H.-M., Ruef, J., Muller-Hulsbeck, S., Jahnke, T., … Scheinert, D. (2009). Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. JOURNAL OF ENDOVASCULAR THERAPY, 16(3), 261–269. https://doi.org/10.1583/08-2676.1
Chicago author-date
Bosiers, Marc, Giovanni Torsello, Hans-Martin Gissler, Johannes Ruef, Stefan Muller-Hulsbeck, Thomas Jahnke, Patrick Peeters, et al. 2009. “Nitinol Stent Implantation in Long Superficial Femoral Artery Lesions: 12-Month Results of the DURABILITY I Study.” JOURNAL OF ENDOVASCULAR THERAPY 16 (3): 261–69. https://doi.org/10.1583/08-2676.1.
Chicago author-date (all authors)
Bosiers, Marc, Giovanni Torsello, Hans-Martin Gissler, Johannes Ruef, Stefan Muller-Hulsbeck, Thomas Jahnke, Patrick Peeters, Kim Daenens, Johannes Lammer, Herman Schroe, Klaus Mathias, Renate Koppensteiner, Frank Vermassen, and Dierk Scheinert. 2009. “Nitinol Stent Implantation in Long Superficial Femoral Artery Lesions: 12-Month Results of the DURABILITY I Study.” JOURNAL OF ENDOVASCULAR THERAPY 16 (3): 261–269. doi:10.1583/08-2676.1.
Vancouver
1.
Bosiers M, Torsello G, Gissler H-M, Ruef J, Muller-Hulsbeck S, Jahnke T, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. JOURNAL OF ENDOVASCULAR THERAPY. 2009;16(3):261–9.
IEEE
[1]
M. Bosiers et al., “Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study,” JOURNAL OF ENDOVASCULAR THERAPY, vol. 16, no. 3, pp. 261–269, 2009.
@article{1022620,
  abstract     = {{Purpose:To evaluate the long-term efficacy and integrity of the PROTEGE EverFlex stent in superficial femoral artery (SFA) lesions in symptomatic patients with peripheral artery disease (PAD).
Methods: A prospective, multicenter, nonrandomized study enrolled 151 subjects (111 men; mean age 67.8 years, range 42-93) undergoing percutaneous treatment of de novo, restenotic, or reoccluded SFA lesions between August 11, 2006, and June 26, 2007. Subjects were scheduled to receive a single stent and be evaluated through 12 months following the implant procedure. Occlusions were present in 40% of the patients. Mean lesion length was 96.4 mm (range 10-150).
Results: A total of 161 stents (158 EverFlex) were implanted in the 151 patients: single stents in 93.4% (141/151) and a second stent in 6.6% (10/151). One-year follow-up information was available for 88.7% (134/151) of the study participants; of the remaining 17 subjects, 6 subjects withdrew from the study, 2 were lost to follow-up, and 9 died. Freedom from restenosis data were available for 99.3% (133/134) of the subjects who completed a 12-month follow-up visit. The mean Rutherford classification fell from 2.8 +/- 0.8 (range 1-5) at baseline to 0.6 +/- 1.1 (range 0-5) at 12 months. The mean ankle-brachial index rose from 0.6 +/- 0.2 (range 0-1.4) at baseline to 0.9 +/- 0.2 (range 0-1.2) at 12 months. The rates for freedom from >50% restenosis at 6 and 12 months were 91.3% (95% Cl 84.9% to 95.2%) and 72.2% (95% Cl 63.8% to 79.6%), respectively. The freedom from target lesion revascularization rate at 12 months was 79.1% (95% Cl 71.2% to 85.6%). The 1-year stent fracture rate was 8.1% (95% Cl 4.0% to 14.4%).
Conclusion: The high freedom from >50% restenosis and low fracture rate at 12 months suggests that the PROTEGE EverFlex stent offers a safe and acceptably efficacious means of treating SFA lesions in symptomatic subjects with PAD. J Endovasc Ther. 2009;16:261-269}},
  author       = {{Bosiers, Marc and Torsello, Giovanni and Gissler, Hans-Martin and Ruef, Johannes and Muller-Hulsbeck, Stefan and Jahnke, Thomas and Peeters, Patrick and Daenens, Kim and Lammer, Johannes and Schroe, Herman and Mathias, Klaus and Koppensteiner, Renate and Vermassen, Frank and Scheinert, Dierk}},
  issn         = {{1526-6028}},
  journal      = {{JOURNAL OF ENDOVASCULAR THERAPY}},
  keywords     = {{occlusions,stenosis,restenosis,TRIAL,stent fracture,outcome analysis,ANGIOPLASTY,peripheral artery disease,superficial femoral artery}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{261--269}},
  title        = {{Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study}},
  url          = {{http://doi.org/10.1583/08-2676.1}},
  volume       = {{16}},
  year         = {{2009}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: